Search
forLearn
5 / 801 resultslearn TDM-105795
learn PTT-6®
learn SDA 40
learn KX-826
Research
5 / 565 resultsresearch S100A6: molecular function and biomarker role
S100A6 is important for cell functions and can help diagnose and treat diseases.
research Ultrastructural Localization of S100A3, a Cysteine-rich, Calcium Binding Protein, in Human Scalp Hair Shafts Revealed by Rapid-freezing Immunocytochemistry
S100A3 protein is mainly found in specific parts of human hair cells.
research Gene Expression of Mouse S100A3, a Cysteine-Rich Calcium-Binding Protein, in Developing Hair Follicle
S100A3 protein is crucial for hair shaft formation in mice.
research Selective Expression of Calcium-Binding Proteins S100A8 and S100A9 at Distinct Sites of Hair Follicles
S100A8 and S100A9 proteins help form hair shafts during growth.
research S100A6 Protein—Expression and Function in Norm and Pathology
S100A6 protein is linked to disease progression, especially in cancers.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community Black market pp405? Title title
PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.